<DOC>
	<DOC>NCT00879333</DOC>
	<brief_summary>This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.</brief_summary>
	<brief_title>Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male or female patients &gt; 18 years old Histologically or cytologically confirmed and documented gastric adenocarcinoma Documented progression after 1 or 2 prior chemotherapy treatments for advanced disease ECOG Performance Status of &lt; 2 Lab parameters within specifically defined intervals Able to provide written informed consent Patients who have received &gt; 2 prior systemic therapies for advanced disease Administration of another anticancer therapy within 3 weeks prior to randomization Chronic treatment with steroids or another immunosuppressive agent Major surgery within 2 weeks prior to randomization Patients with CNS metastases Any other severe and/or uncontrolled medical condition Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Gastric cancer,</keyword>
	<keyword>advanced gastric cancer,</keyword>
	<keyword>stomach neoplasm,</keyword>
	<keyword>stomach disease,</keyword>
	<keyword>adenocarcinoma of stomach,</keyword>
	<keyword>GI neoplasm</keyword>
</DOC>